Current research involves the use of antisense oligonucleotide therapies (ASOs) to target inactivation of DUX4, and the success of ASOs for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy provide a regulatory pathway for those chemistries [7, 8]. This evidence concerns the gene DUX4 and Duchenne muscular dystrophy.